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ABSTRACT
Bcl-2 is often upregulated in cancers to neutralize the BH3-only protein Bim 
at the mitochondria. BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by 
targeting Bcl-2’s hydrophobic cleft and disrupting Bcl-2/Bim complexes. Some cancers 
with elevated Bcl-2 display poor responses towards BH3 mimetics, suggesting an 
additional function for anti-apoptotic Bcl-2 in these cancers. Indeed, Bcl-2 via its 
BH4 domain prevents cytotoxic Ca2+ release from the endoplasmic reticulum (ER) by 
directly inhibiting the inositol 1,4,5-trisphosphate receptor (IP3R). The cell-permeable 
Bcl-2/IP3R disruptor-2 (BIRD-2) peptide can kill these Bcl-2-dependent cancers by 
targeting Bcl-2’s BH4 domain, unleashing pro-apoptotic Ca2+-release events. We 
compared eight “primed to death” diffuse large B-cell lymphoma cell lines (DLBCL) for 
their apoptotic sensitivity towards BIRD-2 and venetoclax. By determining their IC50 
using cytometric cell-death analysis, we discovered a reciprocal sensitivity towards 
venetoclax versus BIRD-2. Using immunoblotting, we quantified the expression levels 
of IP3R2 and Bim in DLBCL cell lysates, revealing that BIRD-2 sensitivity correlated 
with IP3R2 levels but not with Bim levels. Moreover, the requirement of intracellular 
Ca2+ for BIRD-2- versus venetoclax-induced cell death was different. Indeed, BAPTA-
AM suppressed BIRD-2-induced cell death, but promoted venetoclax-induced cell 
death in DLBCL cells. Finally, compared to single-agent treatments, combining BIRD-
2 with venetoclax synergistically enhanced cell-death induction, correlating with a 
Ca2+-dependent upregulation of Bim after BIRD-2 treatment. Our findings suggest 
that some cancer cells require Bcl-2 proteins at the mitochondria, preventing Bax 
activation via its hydrophobic cleft, while others require Bcl-2 proteins at the ER, 
preventing cytotoxic Ca2+-signaling events via its BH4 domain.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and 
chronic lymphocytic leukemia (CLL) are amongst the most 
prevalent lymphoproliferative malignancies, characterized 
by an aggressive or indolent clinical behavior, respectively. 
A combination of chemo-, radio- and immunotherapy 
are currently used to treat patients suffering from non-
Hodgkin lymphoma. Although the standard therapy 
varies according to the lymphoma subtype, often a 
cocktail of cytotoxic drugs in combination with an anti-
CD20 monoclonal antibody (like rituximab®) is used in 
DLBCL. Still, a significant proportion of patients (29% 
of CD20-positive B-cell malignancies [1]) experiences 
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side effects or relapse after rituximab® treatment due to 
tumorescape mechanisms like downregulation of CD20 
protein expression [2]. Another important survival 
strategy of these B-cell malignancies is their upregulation 
of anti-apoptotic Bcl-2 proteins. Indeed, cancer cells are 
addicted to Bcl-2 for their survival due to their continuous 
and permanent ongoing apoptotic signaling [3]. Bcl-2 is 
the founding member of the Bcl-2 family. Along with 
Bcl-XL, Bcl-W, Bfl-1 and Mcl-1 it belongs to the anti-
apoptotic members. These proteins are composed of four 
Bcl-2 homology (BH) domains. On the opposite side, the 
pro-apoptotic family members also consist out of 4 BH 
domains (like Bax and Bak) or have only one (the BH3-
only proteins; like Bim) [4]. For many years it is known 
that anti-apoptotic Bcl-2 via its hydrophobic cleft, formed 
by the BH1-3, scaffolds and neutralizes pro-apoptotic 
members of the Bcl-2 family, including the executioner 
proteins, Bax and Bak, and the BH3-only proteins, like 
Bim [5]. Additionally, the BH4 domain of Bcl-2 prevented 
Bax activation by binding to its inactive conformation [6]. 
This situation where Bcl-2 is loaded with pro-apoptotic 
family members has been referred to as “primed to 
death” [7]. Insights into the binding of Bcl-2 with the 
pro-apoptotic members have spurred the development 
of the BH3 mimetics. These molecules mimic the BH3 
domain of Bad, a sensitizer BH3-only protein thereby 
disrupting Bcl-2/Bim complexes and releasing Bim 
from the hydrophobic cleft of Bcl-2, which then results 
in Bax/Bak-mediated apoptosis in cancer cells but not in 
healthy cells [8, 9]. Nowadays, a Bcl-2-selective BH3-
mimetic compound, ABT-199 (venetoclax) established 
by AbbVie is currently implemented to treat 17p-deleted 
CLL patients [10] without affecting platelet survival [11–
13]. Unfortunately, some Bcl-2-dependent cancer cells 
are insensitive to BH3-mimetic compounds [11], likely 
due to low levels of Bim and/or of Bax/Bak. As such, 
at the level of the mitochondria, these cells are poorly 
“primed to death”. Moreover, patients suffering from 
these poorly-primed cancers also display poor responses 
to conventional chemotherapeutic drugs and thus seem 
hard to treat [14].
Interestingly, for treating cancer cells with 
upregulated Bcl-2 levels, which display reduced 
responses to chemotherapy/BH3 mimetics, Bcl-2’s 
function may be used in an alternative way, namely at 
the endoplasmic reticulum (ER), the main intracellular 
Ca2+-storage organelle [15, 16]. A major ER Ca2+-release 
pathway is formed by the inositol 1,4,5-trisphosphate 
(IP3) receptor (IP3R), which impacts several cancer 
hallmarks, including cell death and survival [17]. During 
recent years, it became clear that an important part of 
Bcl-2’s anti-apoptotic properties is due to direct targeting 
and inhibition of IP3Rs [18–20]. Bcl-2/IP3R complex 
formation is dependent on Bcl-2’s BH4 domain, which 
targets the central, modulatory domain of all three IP3R 
isoforms [21–23]. Importantly, Bcl-2’s hydrophobic cleft 
is dispensable for IP3R-complex formation and IP3R 
inhibition [24]. Consistent with this, venetoclax does 
neither interfere with the binding of Bcl-2 to IP3Rs nor 
alleviate the inhibition of IP3R-mediated Ca
2+ release by 
Bcl-2 [24, 25]. Also, a peptide tool comprising the Bcl-2-
binding site on the IP3R (aa 1389-1408 of mouse IP3R1 in 
which Asp1403Asp1404 residues were changed into two Ala 
residues) was developed, called Bcl-2/IP3R disruptor-2 
(BIRD-2) [26]. BIRD-2 targets the BH4 domain of Bcl-
2, thereby disrupting Bcl-2/IP3R complexes and thus 
abolishing Bcl-2’s inhibitory action on the IP3R channel, 
but not Bcl-2/Bim complexes [18]. BIRD-2 by itself is 
sufficient to kill Bcl-2-dependent CLL and DLBCL 
cancer cells by provoking spontaneous, pro-apoptotic 
Ca2+ signals [26, 27]. Importantly, BIRD-2 does not cause 
a general cytotoxicity. Several cell types were found to 
be very resistant to BIRD-2, e.g. peripheral mononuclear 
blood cells [26], certain types of DLBCL cells [27], non-
malignant cell lines, like WEHI7.2 T cells that express low 
endogenous Bcl-2 levels [26], and platelets (unpublished 
data). In addition, the cell-death properties of BIRD-2, 
which are in lymphoid malignancies accompanied by 
Bax and caspase-3 activation, also provoked a marked 
decrease in in vivo tumor growth in xenografted mouse 
models [28]. Remarkably, in these lymphoma cell lines 
susceptibility to BIRD-2-induced Ca2+ release and cell 
death correlated with the expression level of IP3R2. IP3R2 
is the isoform with the highest sensitivity towards its 
ligand, IP3 [29]. Among DLBCL cancer cells, SU-DHL-4 
cells displayed the highest IP3R2 level and highest BIRD-
2 sensitivity, while OCI-LY-1 displayed the lowest IP3R2 
level and lowest BIRD-2 sensitivity [27]. Interestingly, 
previous studies indicated that OCI-LY-1 were more 
sensitive to BH3 mimetics like the non-selective Bcl-2/
Bcl-XL inhibitor ABT-737 [30] and the selective Bcl-2 
inhibitor venetoclax [11] than SU-DHL-4. Yet, a more 
detailed analysis directly comparing and correlating 
the response of a larger set of different Bcl-2-dependent 
DLBCL cancer cells to BIRD-2 versus venetoclax has not 
been performed.
RESULTS
Heterogeneous responses in DLBCL cell lines 
towards venetoclax treatment
A collection of cancer cell lines mainly composed 
of germinal center DLBCL cells, which are highly 
dependent on Bcl-2 to survive the continuous and 
permanent death signaling, was used in the present study. 
Although, all the cells displayed high levels of Bcl-2 
and were identified to be dependent on Bcl-2 for their 
survival [30], they differently responded to ABT-199 
(venetoclax) treatment [11]. We wanted to validate the 
differential apoptotic sensitivity towards venetoclax in our 
collection of hematological cancer cell lines. To challenge 
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our findings, we also included an internal (negative) 
control, i.e. a DLBCL cell line (PFEIFFER) that was not 
dependent on Bcl-2, but expresses high levels of Bfl-1 
mRNA and therefore was described as being putatively 
Bfl-1 dependent [30]. Hence, we exposed the cells to 
increasing concentrations of venetoclax and determined 
the apoptosis fraction after 24 hours of venetoclax 
treatment (Figure 1A and 1B). The IC50 was determined, 
confirming the differential apoptotic sensitivities in these 
cell lines, listed from high to low sensitivity to venetoclax: 
Ri-1 (IC50= 0.05 μM), OCI-LY-1 (IC50= 0.06 μM), OCI-
LY-18 (IC50= 0.06 μM), TOLEDO (IC50= 0.29 μM), 
SU-DHL-6 (IC50= 1.5 μM), KARPAS-422 (IC50= 3.3 
μM), PFEIFFER (IC50= 4.2 μM) and SU-DHL-4 (IC50= 
10.6 μM). Further, we wanted to validate our data set 
against the results obtained by Souers et al. [11]. These 
data revealed, using linear regression analysis, a strong 
and significant positive correlation (R2= 81%, Figure 2) 
between our experimentally obtained IC50 values and their 
IC50 values [11]. Hence, we could confirm and validate 
the heterogeneity and representativeness of our cell lines 
towards venetoclax.
BIRD-2 sensitivity negatively correlated with 
venetoclax-induced apoptosis in DLBCL cells
Since BIRD-2 and venetoclax target different 
domains of Bcl-2, i.e. the BH4 domain and the hydrophobic 
cleft, respectively, we next examined the sensitivity of 
these cells to BIRD-2. We therefore determined the IC50 
values for BIRD-2-induced cell death (in the following 
rank order from high to low sensitivity to BIRD-2: SU-
DHL-4 (IC50= 9.2 μM), KARPAS-422 (IC50= 13.7 μM), 
TOLEDO (IC50= 16.9 μM), SU-DHL-6 (IC50= 17.8 
μM), OCI-LY-18 (IC50= 19.5 μM), Ri-1 (IC50= 26.1 μM), 
PFEIFFER (IC50= 38.0 μM) and OCI-LY-1 (IC50= 63 
μM)) and correlated them with the IC50 values obtained 
for venetoclax-induced cell death. Interestingly, cells 
previously shown to be sensitive towards venetoclax (Ri-
1, OCI-LY-1 and OCI-LY-18, Figure 1) were more resistant 
towards BIRD-2 treatment (Figure 3A and 3B) and vice 
versa. Moreover, plotting the log IC50 values of both 
compounds against each other for the Bcl-2-dependent cell 
lines revealed an opposite sensitivity between BIRD-2 and 
venetoclax-induced cell death (Figure 4). The correlation 
between BIRD-2 and venetoclax sensitivity was quantified 
by linear regression, showing a significant reciprocal 
correlation between BIRD-2 versus venetoclax sensitivity 
with a R2 value of 61%. Strikingly, the IC50 values for 
BIRD-2 and venetoclax in the Bfl-1-dependent cell line 
PFEIFFER did not follow this reciprocal sensitivity. This 
is consistent that the opposite correlation between both 
Bcl-2 inhibitors is valid for Bcl-2-dependent cancer cells, 
but not for cancer cells dependent on other Bcl-2-family 
members, like Bfl-1. This underpins the “on-target” effect 
of BIRD-2 and venetoclax tools.
IP3R2 protein expression levels positively 
correlated with BIRD-2 sensitivity
Previously, our laboratory has provided evidence 
for the existence of a correlation between the BIRD-2-
induced cell death and the IP3R2 expression levels [27]. 
We thereby showed that there was a good correlation 
with IP3R2, the IP3R isoform with the highest sensitivity 
for the endogenous ligand IP3 [29], but not with the 
other isoforms nor with the total IP3R level, pointing 
to a peculiar role of this IP3R2 isoform in cytotoxic 
Ca2+signaling. We also wanted to examine whether there 
was a correlation between the sensitivity towards BIRD-2 
and the expression levels of the BH3-only protein Bim, 
which is active at the level of the mitochondria. Therefore, 
we quantified the expression levels of IP3R2 and BimEL, 
the most abundant isoform of Bim, in DLBCL cell lysates 
using immunoblotting (normalized to SU-DHL-4, Figure 
5A-5D). These expression levels were plotted with respect 
to the IC50 values obtained for BIRD-2 for each cell line 
(Figure 5E-5F). These data revealed a significant positive 
correlation between the BIRD-2 sensitivity and IP3R2- 
expression levels (R2= 73% Figure 5E), but no correlation 
between the Bim-expression levels and BIRD-2 sensitivity 
was found (R2= 2%, Figure 5F). As a consequence, SU-
DHL-4, KARPAS-422 and TOLEDO cells were good 
responders towards BIRD-2 (Figure 5E) due to their high 
IP3R2 expression levels (Figure 5C). On the other hand, 
OCI-LY-1 has a lower amount of IP3R2 (Figure 5C), which 
correlates with the low sensitivity to BIRD-2 (Figure 5E). 
Also, PFEIFFER expressed lower IP3R2 levels but its 
position in the plot showed a bad correlation with BIRD-2 
sensitivity (data not shown).
Intracellular Ca2+ is required for BIRD-2-, but 
not for venetoclax-induced cell death
In a previous study, we have already observed 
that the BIRD-2-induced apoptosis correlated with 
the BIRD-2-induced Ca2+ release [27]. This together 
with the observation that BIRD-2 positively correlates 
with the IP3R2-expression levels strongly suggest that 
intracellular Ca2+ is important for the BIRD-2-induced 
cell death. To explore the role of Ca2+ in BIRD-2- and 
venetoclax-induced cell death, we measured apoptosis 
while chelating intracellular Ca2+ using BAPTA-AM. We 
first validated that our BAPTA-AM treatment effectively 
chelated intracellular Ca2+ by assessing agonist-induced 
Ca2+ release in Fura-2-loaded SU-DHL-4 cells. Compared 
to untreated cells, cells pre-treated with BAPTA-AM for 
2 hours displayed a severely reduced response to anti-
IgG/IgM, a B-cell receptor agonist that results in IP3/Ca
2+ 
signaling, thereby validating the effectiveness of BAPTA-
AM (Supplementary Figure 1). Adding BAPTA-AM prior 
to BIRD-2 treatment significantly reduced the occurrence 
of cell death in KARPAS-422, OCI-LY-18, Ri-1 and SU-
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Figure 1: The apoptotic response of eight different DLBCL cell lines towards venetoclax treatment. (A) Representative 
dot plots from flow cytometric analysis of Annexin V-FITC/7-AAD stained SU-DHL-4, PFEIFFER, KARPAS-422, SU-DHL-6, TOLEDO, 
OCI-LY-18, OCI-LY-1, and Ri-1 cells, treated with venetoclax at a concentration (indicated in the left top corner of the dot plot) around its 
IC50 value during 24h (10 000 cells per analysis). (B) Concentration-response curves of the 8 different DLBCL cell lines after incubation 
with increasing concentrations of venetoclax for 24h. The apoptotic population was defined as the Annexin V-FITC/7-AAD-positive 
fraction. Data represented are average ± SD (N≥3).
Oncotarget111660www.impactjournals.com/oncotarget
DHL-4 (Figure 6A). A similar protection by BAPTA-AM 
was observed when measuring apoptosis via a caspase-3 
assay (Figure 6B). OCI-LY-1 could not be included in 
this analysis as the concentration of BIRD-2 needed to 
evoke cell death was too high to exclude additional off-
target effects. Oppositely, chelating intracellular Ca2+ upon 
venetoclax treatment significantly enhanced single-agent 
induced cell death and caspase-3 activity in KARPAS-422, 
OCI-LY-1, OCI-LY-18, SU-DHL-4 and Ri-1 cells (Figure 
7A and 7B). Interestingly, the cell death induced by 
BAPTA-AM in the presence of venetoclax seemed to 
correlate with their venetoclax sensitivity, as Ri-1, OCI-
LY-1 and OCI-LY-18 were the most sensitive to BAPTA-
AM and KARPAS-422 and SU-DHL-4 the least sensitive 
ones.
Hence, overall these findings suggest a different 
requirement for Ca2+ in the BIRD-2- or venetoclax-
induced cell death.
Synergistic killing of DLBCL cells by venetoclax 
and BIRD-2
Because BIRD-2 and venetoclax target different 
domains of Bcl-2, we tested whether combining these 
agents would synergistically induce cell death. Combining 
a submaximal concentration of BIRD-2 with increasing 
concentrations of venetoclax enhanced cell-death induction 
in the venetoclax-resistant SU-DHL-4 DLBCL cell line 
compared to single-agent treatment (Figure 8A). In order 
to determine mathematically whether it is a synergistic or 
additive effect, a combination index (CI) was measured. As 
a CI<1 indicates synergy, co-treatment of SU-DHL-4 with 
BIRD-2 and venetoclax consistently induced synergistic 
cytotoxicity at all concentration measured. Additionally, 
similar results were obtained when calculating the CI using 
the raw data set (Supplementary Figure 2) instead of the 
change in apoptotic fraction. Moreover, we demonstrated 
that treating the highly BIRD-2-sensitive SU-DHL-4 
cell line with 3 μM BIRD-2, a concentration ineffective 
to trigger cell death by itself, significantly increased the 
Bim levels, thereby priming the cells for sensitivity to 
venetoclax (Figure 8B). Moreover, the BIRD-2-induced 
upregulation of Bim seemed to be Ca2+ dependent, since 
chelating intracellular Ca2+ with BAPTA-AM could 
suppress the BIRD-2-induced upregulation of Bim.
Together with the existence of a reciprocal 
correlation, these data underpin differences in the targets 
for apoptotic induction by BIRD-2 or venetoclax.
DISCUSSION
Anti-apoptotic Bcl-2 protects cancer cells from cell 
death by acting at the mitochondria, scaffolding Bim/Bak/
Bax [6] and by acting at the ER, suppressing excessive 
IP3Rs activity [31]. Here, we used a collection of well-
established Bcl-2-dependent DLBCL cell lines to assess 
the cell-death properties of two selective Bcl-2 inhibitors 
that target different domains of Bcl-2, namely ABT-199 
(venetoclax), which targets the hydrophobic cleft of Bcl-
2 and disrupts Bcl-2/Bim interactions [11], and BIRD-2, 
which targets the N-terminal BH4 domain of Bcl-2 and 
disrupts IP3R/Bcl-2 interactions [21]. Plotting the IC50 
values for the apoptotic effect of both Bcl-2 inhibitors 
revealed a reciprocal sensitivity between venetoclax and 
BIRD-2 in the cancer cells dependent on Bcl-2 for their 
survival. This reciprocal sensitivity between venetoclax 
and BIRD-2 appeared to count for Bcl-2-dependent 
cancer cells, but not for Bfl-1-dependent cancer cells, 
as the Bfl-1-dependent cancer cell line PFEIFFER was 
relatively resistant to both venetoclax and BIRD-2. This 
correlates with previous work showing that increased 
transcript levels of Bfl-1 has been allocated to resistance 
Figure 2: Positive correlation between the IC50 values for venetoclax determined in this project and previously 
published IC50 values. Linear regression analysis of the IC50 values obtained for venetoclax from the concentration-response curves of 
Figure 1 against the previously published results obtained by Souers et al. [11] for respectively six different DLBCL cell lines.
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Figure 3: Heterogeneity in the apoptotic response of eight different DLBCL cell lines towards BIRD-2 treatment. 
(A) Representative dot plots from flow cytometric analysis of Annexin V-FITC/7-AAD-stained SU-DHL-4, KARPAS-422, SU-DHL-6, 
TOLEDO, OCI-LY-18, Ri-1, PFEIFFER and OCI-LY-1 cells, treated with BIRD-2 at a concentration (indicated in the left top corner of 
the dot plot) around its IC50 value, during 24h (10 000 cells per analysis). (B) Concentration-response curves of the different DLBCL cell 
lines after incubation with increasing concentrations of BIRD-2 for 24h. The apoptotic population was identified as the Annexin V-FITC/7-
AAD-positive fraction. Data represented are average ± SD (N≥3).
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to BH3 mimetics [32]. We also wish to note that the range 
of sensitivities of the different DLBCL cells obtained 
for BIRD-2 versus venetoclax are very different, being 
~6-fold different for BIRD-2, while being ~200-fold 
different for venetoclax. The reason for this difference is 
not clear, but may relate to differences in uptake rate and 
mechanisms and in their underlying mechanism of action. 
In any case, the range of sensitivities obtained in this work 
for BIRD-2 and venetoclax are very similar to the ones 
previously reported in the literature [11, 27, 28, 33].
Though our study is the first to have systematically 
compared and correlated the sensitivity of a collection 
of DLBCL cell lines towards venetoclax versus BIRD-2 
by performing complete and quantitative concentration-
response analyses, previous studies have hinted towards 
such a concept. Indeed, previous work from our own 
lab focusing on SU-DHL-4 versus OCI-LY-1 and short-
term apoptosis experiments showed that the venetoclax-
sensitive OCI-LY-1 cells were resistant to 10 μM BIRD-2, 
while SU-DHL-4, a cell line less sensitive to venetoclax 
was sensitive to 10 μM BIRD-2 [27]. Follow-up work 
by Distelhorst and co-workers in multiple myeloma cells 
[28] and small cell lung carcinoma [34], using a single 
concentration of BIRD-2 and of BH3 mimetics, confirmed 
that cell lines more resistant to BH3 mimetics were more 
sensitive to BIRD-2 and vice versa. We now provide 
further insight in the reciprocal sensitivity of cancer cells to 
venetoclax versus BIRD-2. Previous work from Letai and 
co-workers showed that responsiveness to BH3 mimetics 
correlated with Bim levels and more particular with 
Bcl-2/Bim complex formation [30]. Here, we show that 
BIRD-2 sensitivity positively correlates with IP3R2 levels 
while there was no correlation with Bim levels. Hence, 
these data support the concept of the dual dependence 
of cancer cells on Bcl-2 for their survival with respect to 
the oncogenic signaling either by Bim upregulation or by 
IP3R2 upregulation. Of note, Bcl-2 also interacts with the 
regulatory and coupling domain of the IP3R isoform 1 and 
isoform 3 [22] and is able to form protein complexes with 
all three IP3R isoforms in Jurkat and WEHI7.2 T cells [18, 
35]. This correlates with the high level of conservation 
of the 20-amino acid stretch encompassing the Bcl-2-
binding site among the different IP3R isoforms [36–38]. 
However, in DLBCL cells, it seems that Bcl-2 interaction 
with the different IP3R isoforms is context dependent. In 
SU-DHL-4, Bcl-2 co-immunoprecipitated predominantly 
with IP3R2 when compared with IP3R3, while in OCI-
LY-1 the reverse was observed [27]. The reason for this 
is not clear, but may indicate a differential modulation 
of IP3R isoforms and Bcl-2 in different cellular contexts. 
In any case, both the intracellular Ca2+ release and the 
apoptotic response induced by BIRD-2 correlated with 
IP3R2-expression levels but not with IP3R1- or IP3R3-
expression levels. The binding of Bcl-2 to IP3R2, which 
displays the highest sensitivity to its ligand IP3, and the 
concomitant suppression of IP3R2 activity may enable 
cancer cell survival in two ways: (i) by preventing the 
occurrence of excessive, pro-apoptotic Ca2+-release events 
and (ii) by establishing low-level Ca2+ signaling that drives 
the mitochondrial metabolism of cancer cells [39, 40]. In 
addition to this, IP3R2 upregulation has been implicated in 
cellular senescence, a stable growth arrest that prevents the 
proliferation of malignant cells [41]. Therefore, the binding 
of Bcl-2 to IP3R2 may allow cancer cells to escape cellular 
senescence. The oncogenic mechanisms responsible for 
IP3R2 upregulation remain largely unknown, although a 
role for constitutive NFAT signaling may be part of the 
signaling mechanisms that cause IP3R2 upregulation 
[42]. Furthermore, it is also unknown which mechanisms 
or checkpoints are in place that are responsible for the 
‘choice’ of upregulating Bim versus IP3Rs in response to 
oncogenic stress. It is conceivable that the upregulation 
Figure 4: The IC50 values of the analysed DLBCL cell lines indicate an opposite response to BIRD-2 versus venetoclax. 
The different IC50 values were determined via the concentration-response curves (Figures 1 and 3) and the log IC50 values for BIRD-2 were 
plotted as a function of the log IC50 values for venetoclax. These IC50 values were subjected to statistical analysis via linear regression.
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of Bim or IP3R2 in cancer cells ought to be compensated 
by high anti-apoptotic Bcl-2 levels resulting in protein 
complexes with either Bim or IP3R2. Because the IP3R2 
is an important mediator of the BIRD-2 susceptibility, 
we examined in more detail the role of intracellular 
Ca2+ in the BIRD-2- and venetoclax-induced cell death. 
We confirmed earlier work [27, 28], pinpointing to an 
important role for intracellular Ca2+ overload in BIRD-
2-induced cell death, since intracellular Ca2+ buffering 
decreased caspase-3 activation in response to BIRD-2 
treatment in different DLBCL cell lines. In addition to 
this, it is possible that BAPTA-AM can suppress BIRD-
2-induced cell death by counteracting the upregulation of 
pro-apoptotic BH3-only protein Bim brought about by 
BIRD-2 treatment. In contrast, chelating intracellular Ca2+ 
enhanced the venetoclax-induced caspase-3 activation in 
different DLBCL cell lines. We have already elucidated 
previously that venetoclax did not trigger an acute Ca2+ 
release and that intracellular Ca2+ buffers did not protect 
against venetoclax-induced cell death in OCI-LY-1 and 
SU-DHL-4 cells [25]. Here we extended our earlier work 
to several DLBCL cell lines, firmly excluding an essential 
role for intracellular Ca2+ overload for venetoclax-induced 
cell death. On the contrary, it seems that DLBCL cells 
Figure 5: Positive correlation between the IP3R2 levels and the BIRD-2 sensitivity. (A-B) Representative western blots of 
the IP3R2 (A) and BimEL (B) expression levels. GAPDH was used as loading control. (C-D) Quantification of IP3R2 (C) and BimEL (D) 
expression levels. Data are represented as the average ± SD of N≥3 with ** p<0.01 and ***p<0.001 obtained via a repeated measure ANOVA 
with a Bonferroni’s post-hoc test versus SU-DHL-4. (E-F) Correlation between the expression levels of IP3R2 (E) and BimEL (F) with the 
IC50 values of BIRD-2, subjected to statistical analysis via linear regression.
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Figure 6: Intracellular Ca2+ has a primary role in the BIRD-2-induced cell death. Analysis of Annexin V-FITC/7-AAD-
negative cells (living cells (%), A) and caspase-3-negative cells (B) obtained using flow-cytometric analysis of KARPAS-422, OCI-LY-18, 
Ri-1 and SU-DHL-4 cells treated with or without BIRD-2 and 10 μM BAPTA-AM for 2h. Data are represented as mean ± SEM >3 
independent experiments. Significance was obtained using a two-tailed paired t-test with * p< 0.05, **p<0.01.
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Figure 7: Intracellular Ca2+ does not contribute to the venetoclax-induced cell death. Analysis of Annexin V-FITC/7-
AAD-negative cells (living cells (%), A) and caspase-3-negative cells (B) obtained using flow-cytometric analysis of KARPAS-422, 
OCI-LY-1, OCI-LY-18, Ri-1 and SU-DHL-4 cells treated with or without venetoclax and 10 μM BAPTA-AM for 4h. Data are 
represented as mean ± SEM >3 independent experiments. Significance was obtained using a two-tailed paired t-test with * p< 0.05, 
**p<0.01, ***p<0.001.
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Figure 8: Synergistic effect of BIRD-2 and venetoclax in SU-DHL-4 cells, correlating to Bim upregulation in BIRD-
2-treated SU-DHL-4 cells. (A) SU-DHL-4 cells were treated for 24h with various concentrations of venetoclax alone (black bars), 
BIRD-2 alone (blue bars) or a combination of venetoclax/DMSO Ctrl (0.03%) and BIRD-2 (red bars). Cell death was measured using flow 
cytometry of Annexin V-FITC/7-AAD-stained cells and plotted as the BIRD-2- or venetoclax-induced apoptotic fraction. The combination 
index, calculated using the response additive method (CI= (Evenetoclax+ EBIRD-2)/Evenetoclax+BIRD-2) was measured as indication for synergistic or 
additive cell killing. Data are represented as average ± SEM of N=5. Statistical significance was determined with a two-way ANOVA with 
a Bonferroni post-hoc test comparing Evenetoclax or EBIRD-2 with Evenetoclax+BIRD-2 for the different venetoclax concentrations. (B) Representative 
western blots showing the BimEL-expression levels after 24h treatment of SU-DHL-4 cells with 3 μM BIRD-2 in the presence or absence 
of 10 μM BAPTA-AM. Vinculin was used as loading control. Data are represented as the average ± SD of N≥3 with * p<0.05 obtained via 
Wilcoxon signed rank test.
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can be sensitized to venetoclax by buffering intracellular 
Ca2+. The mechanisms underlying the interplay between 
venetoclax and basal Ca2+ signals in DLBCL are not clear 
and will require further research. However, it is possible 
that BAPTA-AM treatment disturbs the balance between 
pro-apoptotic and anti-apoptotic Bcl-2-family members. 
For instance, ovarian cancer cells exposed to BAPTA-AM 
display a reduction in the protein levels of anti-apoptotic 
Mcl-1 [43]. Hence, such decreases in the levels of anti-
apoptotic proteins and/or increases in the levels of pro-
apoptotic proteins may account for the toxic effects of 
BAPTA-AM and/or sensitization towards BH3-mimetic 
drugs.
In addition, combing BIRD-2 with venetoclax 
enhanced cell demise compared to single treatment alone 
in a venetoclax-resistant DLBCL cell line. Hence, co-
treatment with BIRD-2 could sensitize the cells towards 
venetoclax. Previous reports also indicated a synergistic 
effect between BIRD-2 and BH3 mimetics in melanoma 
[28] and lung cancer cells [34]. In melanoma cells 
prolonged exposure to BIRD-2 increased the protein levels 
of Bim in a Ca2+-dependent manner and consequently 
increased the sensitivity towards BH3 mimetics [28]. 
We here report that the BIRD-2-dependent upregulation 
of Bim also occurs in DLBCL cells in a Ca2+-dependent 
manner, thereby sensitizing these cancer cells towards 
venetoclax and thus likely underlying the synergism 
between BIRD-2 and venetoclax for inducing cell death 
in DLBCL cells. This synergism also establishes an 
interesting link between the “ER Ca2+ signaling” pathways 
and “mitochondrial BH3-only” pathways in apoptosis, 
where Ca2+ signals may not only by themselves trigger 
apoptosis, e.g. by mitochondrial Ca2+ overload, but may 
also affect the expression levels of other Bcl-2-family 
members, thereby modulating cell death. This intriguing 
link between Ca2+ signaling and Bcl-2-family members is 
further underpinned by the fact that venetoclax-induced 
cell death can be enhanced by intracellular Ca2+ chelation 
using BAPTA-AM.
Our collection of data is also consistent with the dual 
role of anti-apoptotic Bcl-2 being either inhibiting pro-
apoptotic proteins or suppressing aberrant IP3-mediated Ca
2+ 
release [31]. It may also indicate that different domains of 
Bcl-2 underlie Bcl-2’s differential role at the mitochondria 
(its hydrophobic cleft targetable by BH3-domain-like 
molecules) and at the ER (its BH4 domain targetable by 
IP3R-domain-derived molecules). Indeed, previous work 
indicated that the inhibition of IP3Rs by Bcl-2 critically 
depends on Bcl-2’s BH4 domain [21, 22], while Bcl-2’s 
hydrophobic cleft is dispensable for this [24]. Furthermore, 
by showing that the IP3R2 protein levels correlated with 
the sensitivity to BIRD-2 in the following rank order: 
KARPAS-422 > SU-DHL-4 > OCI-LY-18 > Ri-1 > SU-
DHL-6 > TOLEDO > OCI-LY-1, we confirm the complex 
formation between IP3R2 and Bcl-2 as a major determinant 
for cancer cell addiction to Bcl-2 at the ER. However, other 
confounding factors might further influence the correlation 
between the IP3R2/Bim-expression levels with the BIRD-
2 sensitivity. Indeed, recent reports have indicated that 
the activation of proto-oncogene like PKB/Akt can affect, 
by phosphorylation, both the IP3R function and ER Ca
2+ 
homeostasis and thereby decreasing apoptotic events by 
dampening the mitochondrial Ca2+ rise [44, 45]. Moreover, 
this oncogenic PKB/Akt hyperactivity is often linked to the 
loss of PTEN in DLBCL cells [46]. It is not known whether 
PKB/Akt signaling affects all IP3R subtypes and particularly 
IP3R2 in the same way and thus could modulate BIRD-2-
induced cell death.
Thus, cancer cells can exploit both of the anti-
apoptotic actions of Bcl-2 to promote their survival, 
dependent on the challenging conditions operative in these 
cells, either by Bim upregulation or by IP3R2 upregulation. 
The type of addiction to Bcl-2 will dictate their apoptotic 
sensitivity to BH3 mimetics or BH4-domain-targeting 
compounds. Importantly, the chemotherapeutic response 
of cancer cells appears to correlate with the mitochondrial 
“primed to death” status of Bcl-2 and thus their sensitivity 
to BH3 mimetics [14, 47–49]. This indicates that patients 
displaying a poor response to chemotherapy will also 
display a weak response to BH3 mimetics, as they impinge 
on the same mitochondrial pathway. However, our data 
suggest that these “resistant” cancers might be targeted 
using BH4-domain-targeting tools like BIRD-2. This 
indicates that patients with a poor clinical response to 
chemotherapy due to poor mitochondrial priming may 
benefit from BH4-domain-antagonizing compounds, like 
BIRD-2. Further work is needed on the identification of 
BH4-domain-antagonizing molecules that are applicable 
in vivo. However, this area is also in vivid expansion, 
recently resulting in the development of BDA-366, a small 
molecule targeting the BH4 domain of Bcl-2 with very 
high affinity and selectivity compared to Bcl-XL [50]. The 
mechanism of action of BDA-366 appeared to involve a 
conformational switch of Bcl-2 from an anti-apoptotic to 
pro-apoptotic protein, thereby exposing its BH3 domain 
and acting as a Bax-activating protein. BDA-366 also 
disrupted IP3R/Bcl-2 complexes [51]. Yet, further work is 
required to validate whether BIRD-2 and BDA-366 share 
a common mechanism of action. As such, BDA-366 might 
be a first promising tool to elicit cell death in cancers that 
are more resistant to BH3 mimetics [50–52].
Overall, our data indicate that BH4-domain-
antagonizing tools like BIRD-2 hold potential to kill Bcl-
2-dependent cancer cells, in particular those that are more 
resistant to chemotherapy and precision medicines like 
venetoclax. By acting on a different functional domain 
of Bcl-2 than BH3 mimetics, these tools could provide 
additional opportunities to kill these cancers, and to be 
used as follow-up strategies to kill venetoclax-resistant 
or -relapsed cancers, or to participate in combination 
therapies with venetoclax via their ability to boost 
endogenous Bim levels.
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MATERIALS AND METHODS
Cells
SU-DHL-4, KARPAS-422, PFEIFFER, TOLEDO, 
SU-DHL-6, OCI-LY-1 and OCI-LY-18 DLBCL cell lines 
were kindly obtained from Dr. Anthony Letai (Dana-
Farber Cancer Institute, Boston, Massachusetts, USA), 
who performed a complete “BH3 profiling” analysis 
of these cell lines [30]. The Ri-1 DLBCL cell line was 
ordered via DSMZ (Braunschweig, Germany). All these 
cell lines were authenticated by the University of Arizona 
Genetics Core (Tucson, AZ, USA) using autosomal short 
tandem repeat (STR) profiling via Science Exchange 
(www.scienceexchange.com). The results were validated 
using reference databases such as DSMZ (Germany) and 
sample profiles (allelic values) and electropherogram trace 
data were provided. All cell lines except one displayed 
a perfectly matched profile with 8 tested alleles (8/8), 
while for SU-DHL-6 cells 7/8 alleles matched. The 
apoptotic response of these cells to different venetoclax 
concentrations was validated and benchmarked against 
the published venetoclax IC50 values by Souers et al [11]. 
The SU-DHL-4, KARPAS-422, PFEIFFER, TOLEDO, 
Ri-1 and SU-DHL-6 DLBCL cell lines were cultured 
in suspension in RPMI-1640 media. The OCI-LY-1 and 
OCI-LY-18 DLBCL cell lines were cultured in suspension 
in Iscove modified Dulbecco medium (Invitrogen, 
Merelbeke, Belgium). All media were supplemented with 
10% heat-inactivated fetal bovine serum, L-glutamine (100 
× GlutaMAX, Gibco/Invitrogen, Merelbeke, Belgium) 
and penicillin and streptomycin (100 × Pen/Strep, Gibco/
Invitrogen, Merelbeke, Belgium) and cultured at 37°C and 
5% CO2.
Antibodies and reagents
Immunoblotting was performed with anti-GAPDH 
(Sigma-Aldrich, Munich, Germany), anti-vinculin (Sigma-
Aldrich, Munich, Germany), anti-IP3R2 (Rbt02 [53]) and 
anti-Bim (Bioké, Leiden, The Netherlands).
BIRD-2 (RKKRRQRRRGGNVYTEIKCNSLLP
LAAIVRV) (purity>85%) was purchased from LifeTein 
(South Plainfield, New Jersey, USA) and venetoclax from 
Active Biochem (Bonn, Germany).
Western blotting
DLBCL cells were washed with phosphate-buffered 
saline and incubated at 4°C with lysis buffer (20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 0.5 mM 
dithiothreitol, 1% Triton X-100, 1 tablet complete EDTA-
free protease inhibitor per 50 ml (Thermo Scientific, 
Brussels, Belgium) for 30 min on a head-over-head rotor. 
Cell lysates were centrifuged for 5 minutes at 10 000 rpm. 
Twenty μg of protein sample was loaded on a NuPAGE 
3-8% Tris-Acetate protein gel for the detection of the 
IP3R2 protein and for the detection of the Bim protein a 
NuPAGE 4-12% Bis-Tris protein gel (Life Technologies, 
Brussels, Belgium) was used for western blotting as 
previously described [22].
Apoptosis assay
After treatment (see figure legends for 
more information about the treatment, time and 
concentration) DLBCL cells (5 × 105 cells/ml) were 
pelleted by centrifugation, and incubated with Annexin 
V-FITC (Life Technologies, Brussels, Belgium) and 
7-aminoactinomycin D (7-AAD) (Life Technologies, 
Brussels, Belgium) or with 2.5 μM NucviewTM 488 
caspase-3 substrate (Biotium, CA, USA) for 15 or 30 
minutes respectively. Cell suspensions were analyzed with 
an Attune® Acoustic Focusing Flow Cytometer (Applied 
Biosystems, Brussels, Belgium). Cell death was scored by 
quantifying the population of Annexin V-FITC-positive 
and 7-AAD positive cells or by quantifying the caspase-3 
positive cells.
Cytosolic Ca2+ measurements in intact cell 
populations
SU-DHL-4 cells were loaded for 30 min with 1.25 
μM Fura-2 AM at room temperature in modified Krebs 
solution (150 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 
11.6 mM HEPES pH 7.3, 11.5 mM glucose and 1.5 mM 
CaCl2). Afterwards, 400 000 cells were seeded in poly-
L-lysine coated 96-well plates (Greiner, Vilvoorde, 
Belgium) and incubated for at least 30 minutes in the 
absence of Fura-2 AM. Fluorescence was monitored on 
a FlexStation3 microplate reader (Molecular Devices, 
CA, USA) by alternately exciting the Ca2+ indicator at 
340 and 380 nm and collecting emission fluorescence at 
510 nm. After 60 seconds agonist-induced Ca2+ release 
was induced by adding 12 μg/ml anti-IgG/IgM (Sanbio, 
Uden, The Netherlands). All traces are shown as the ratio 
of emitted fluorescence of Fura-2 (F340/F380).
Statistical analysis
Results from the western blot analysis are expressed 
as average ± SD whereby N refers to the number of 
independent experiments. Significance was determined 
using a repeated measures one-way ANOVA with a 
Bonferroni’s post hoc test for the IP3R and Bim expression 
levels. Statistical significance of the Bim expression levels 
after BIRD-2 treatment in the absence or presence of 
BAPTA-AM was performed with a Wilcoxon signed rank 
test. Differences were considered significant at p<0.05. 
Correlation of the different IC50 values with each other 
and with the protein expression levels were statistically 
analysed via linear regression.
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As indicative of synergy between BIRD-2 and 
venetoclax treatment the Combination Index (CI) was 
calculated by making the ratio of the theoretical sum of 
the individual effects (Evenetoclax+ EBIRD-2) with the effect 
of combining the treatments (Evenetoclax+BIRD-2). Statistical 
significance was determined with a two-way ANOVA 
with a Bonferroni post-hoc test comparing Evenetoclax or 
EBIRD-2 with Evenetoclax+BIRD-2 for the different venetoclax 
concentrations.
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